Arylstibonic acids are potent and isoform-selective inhibitors of Cdc25a and Cdc25b phosphatases

被引:15
|
作者
Mak, Lok Hang [1 ,2 ]
Knott, Jessica [1 ,2 ]
Scott, Katherine A. [3 ,4 ]
Scott, Claire [5 ]
Whyte, Gillian F. [1 ,2 ]
Ye, Yu [6 ]
Mann, David J. [2 ,3 ]
Ces, Oscar [1 ,2 ]
Stivers, James [6 ]
Woscholski, Rudiger [1 ,2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England
[2] Univ London Imperial Coll Sci Technol & Med, Inst Biol Chem, London SW7 2AZ, England
[3] Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England
[4] Univ London Imperial Coll Sci Technol & Med, Ctr Drug Discovery, London W6 8RP, England
[5] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, London SW7 2AZ, England
[6] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
基金
英国工程与自然科学研究理事会;
关键词
Arylstibonic acids; Protein tyrosine phosphatase; Cdc25; inhibitor; PROTEIN-TYROSINE PHOSPHATASES; MECHANISM; 5-PHOSPHATASES; CANCER; CELLS; PTEN; HEAD;
D O I
10.1016/j.bmc.2012.05.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Arylstibonates structurally resemble phosphotyrosine side chains in proteins and here we addressed the ability of such compounds to act as inhibitors of a panel of mammalian tyrosine and dual-specificity phosphatases. Two arylstibonates both possessing a carboxylate side chain were identified as potent inhibitors of the protein tyrosine phosphatase PTP-beta. In addition, they inhibited the dual-specificity, cell cycle regulatory phosphatases Cdc25a and Cdc25b with sub-micromolar potency. However, the Cdc25c phosphatase was not affected demonstrating that arylstibonates may be viable leads from which to develop isoform specific Cdc25 inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4371 / 4376
页数:6
相关论文
共 50 条
  • [1] CHROMOSOME MAPPING OF HUMAN CDC25A AND CDC25B PHOSPHATASES
    DEMETRICK, DJ
    BEACH, DH
    [J]. GENOMICS, 1993, 18 (01) : 144 - 147
  • [2] β-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases
    Kanemori, Y
    Uto, K
    Sagata, N
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (18) : 6279 - 6284
  • [3] Overexpression of CDC25A and CDC25B in head and neck cancers
    Gasparotto, D
    Maestro, R
    Piccinin, S
    Vukosavljevic, T
    Barzan, L
    Sulfaro, S
    Boiocchi, M
    [J]. CANCER RESEARCH, 1997, 57 (12) : 2366 - 2368
  • [4] Expression of cdc25A and cdc25B proteins in thyroid neoplasms
    Ito, Y
    Yoshida, H
    Nakano, K
    Kobayashi, K
    Yokozawa, T
    Hirai, K
    Matsuzuka, F
    Matsuura, N
    Kakudo, K
    Kuma, K
    Miyauchi, A
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (12) : 1909 - 1913
  • [5] Expression of cdc25A and cdc25B phosphatase in breast carcinoma
    Ito Y.
    Yoshida H.
    Uruno T.
    Takamura Y.
    Miya A.
    Kuma K.
    Miyauchi A.
    [J]. Breast Cancer, 2004, 11 (3) : 295 - 300
  • [6] NSC-87877 Inhibits Cdc25A and Cdc25B
    Song, Mina
    Cho, Sayeon
    [J]. Bulletin of the Korean Chemical Society, 2009, 30 (04) : 924 - 926
  • [7] NSC-87877 Inhibits Cdc25A and Cdc25B
    Song, Mina
    Cho, Sayeon
    [J]. BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2009, 30 (04): : 924 - 926
  • [8] Expression of cdc25A and cdc25B proteins in thyroid neoplasms
    Y Ito
    H Yoshida
    K Nakano
    K Kobayashi
    T Yokozawa
    K Hirai
    F Matsuzuka
    N Matsuura
    K Kakudo
    K Kuma
    A Miyauchi
    [J]. British Journal of Cancer, 2002, 86 : 1909 - 1913
  • [9] Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis
    Ito, Y
    Yoshida, H
    Tomoda, C
    Uruno, T
    Takamura, Y
    Miya, A
    Kobayashi, K
    Matsuzuka, F
    Kuma, K
    Nakamura, Y
    Kakudo, K
    Miyauchi, A
    [J]. CANCER LETTERS, 2005, 229 (02) : 291 - 297
  • [10] CDC25A: A Rebel Within the CDC25 Phosphatases Family?
    Fernandez-Vidal, Anne
    Mazars, Anne
    Manenti, Stephane
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (08) : 825 - 831